News

Medicilon/MPI Preclinical Research-Shanghai has recently expanded their service offerings to provide Sponsors with the ability to conduct studies that meet the FDA’s Good Laboratory Practice (GLP) regulations, at

BHR Pharma (BHR) has filed an Investigational New Drug (IND) application with the FDA for its proprietary BHR-100 intravenous progesterone infusion product. In September of this year, the

Interleukin Genetics has received approval from the state of New York’s Department of Health, to sell in New York its PST genetic test that determines predisposition to severe

Pfizer and Crown Bioscience (Crown) have entered into a collaboration to research and develop novel therapeutics for Asian cancers. Specific treatments for Asian cancers represent an important unmet

IH Systems has conducted a study which demonstrated that RIVA System (Robotic Intravenous Automation), a self-contained unit for aseptic compounding from Intelligent Hospital Systems (IH Systems), is an

Novartis has reported result of Tasigna Phase III clinical trial. In the study, Tasigna (nilotinib) demonstrated greater efficacy over Glivec (imatinib) in the treatment of adult patients with

Tranzyme Pharma (Tranzyme ) has entered into a strategic collaboration agreement with Bristol-Myers Squibb, to discover, develop and commercialise macrocyclic compounds directed against targets of interest to Bristol-Myers

Allos Therapeutics (Allos) has provided updated data from its ongoing dose finding phase 1 study of Folotyn (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma

FDA has selected MasterControl from SynCardia Systems as the new quality management system for the Food and Drug Administration (FDA). MasterControl also provides the quality management system for